OmniAb to Participate in Two Investor Conferences in September
05 September 2023 - 2:00PM
Business Wire
OmniAb, Inc. (NASDAQ: OABI) today announced that
management will be participating in two upcoming investor
conferences in September.
- H.C. Wainwright 25th Annual Global Investment Conference,
September 11-13, 2023 at the Lotte New York Palace Hotel in New
York City. Management will deliver a company presentation on
Tuesday, September 12th at 9:00 a.m. Eastern time and will be
available for one-on-one meetings with investors. A live and
archived webcast of the presentation will be available in the
Investors section of OmniAb’s website.
- Cantor Fitzgerald Global Healthcare Conference,
September 26-28, 2023 at the InterContinental New York Barclay
in New York City. Management will be hosting one-on-one
meetings during the event.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications though a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. We believe the OmniAb animals
comprise the most diverse host systems available in the industry
and they are optimally leveraged through computational antigen
design and immunization methods, paired with high-throughput single
B cell phenotypic screening and mining of next-generation
sequencing datasets with custom algorithms to identify fully human
antibodies with superior performance and developability
characteristics. These proprietary technologies are joined with and
leverage OmniDeep™, which is a suite of in silico tools for
therapeutic discovery and optimization that are woven throughout
OmniAb’s various technologies and capabilities. Additionally, an
established core competency focused on ion channels and
transporters further differentiates OmniAb’s technology and creates
opportunities in many emerging target classes. OmniAb antibodies
have been leveraged across modalities, including bispecific
antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905595420/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com Twitter (X)
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
OmniAb (NASDAQ:OABI)
Historical Stock Chart
Von Sep 2023 bis Sep 2024